Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 3 1

Status

Completed 11Terminated 6Withdrawn 3

Sponsor Class

NIH 7INDUSTRY 6OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Other hematologic neoplasm 2Sarcoma 1Lymphoid 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Melanoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Gastrointestinal Stromal Tumors 1Breast Neoplasms 1Advanced Malignancies 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × tanespimycin × Clear all
NCT00724425 2015-04-15

A Phase 1 Dose Escalation Study of IPI-493

Infinity Pharmaceuticals, Inc.

Phase 1 Terminated
53 enrolled

Advanced Malignancies

NCT01193491 2015-04-15

Dose Escalation of IPI-493 in Hematologic Malignancies

Infinity Pharmaceuticals, Inc.

Phase 1 Terminated
4 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT00688766 2012-12-11

Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib

Infinity Pharmaceuticals, Inc.

Phase 3 Terminated
47 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT00817362 2012-12-11

Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer

Infinity Pharmaceuticals, Inc.

Phase 2 Terminated
29 enrolled
Breast

Breast Neoplasms

NCT00627419 2012-12-10

A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma

Infinity Pharmaceuticals, Inc.

Phase 2 Terminated
1 enrolled
Dermatologic

Melanoma

NCT00319930 2010-03-08

Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL

Biogen

Phase 1 Terminated
10 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡